Project description
Protecting our planet against pharmaceutical pollution
The contamination of global soil and aquatic ecosystems by pharmaceuticals, antimicrobial-resistant microorganisms, and pathogens is a pressing concern, threatening both our environment and human well-being. With the support of the Marie Skłodowska-Curie Actions programme, the Pharm-ERA project brings together academics, public and private stakeholders, and EU policymakers to address this urgent issue. With 10 doctoral projects spanning scientific disciplines such as environmental chemistry, ecotoxicology, microbial ecology, molecular biology and modelling, Pharm-ERA seeks to develop innovative solutions and improve monitoring techniques and environmental risk assessment. The ultimate aim is to protect the diversity and functions of microbial life in contaminated ecosystems while ensuring the sustainability of our planet and promoting human and animal health.
Objective
Global contamination of soil and aquatic ecosystems by pharmaceutical and microbiological pollutants (such as antimicrobial-resistant microorganisms and/or pathogens) raises severe concerns about impacts on ecosystem health and repercussions on humans and animals. Preserving ecosystems from adverse ecotoxicological effects of pharmaceuticals and their transformation products and limiting the environmental spread of antimicrobial resistance and pathogens is imperative to reach several UN Sustainable Development Goals as well as the European Green Deal, Water Framework Directive and Biodiversity Strategy for 2030. To meet these huge environmental and societal challenges, public and private stakeholders and EU policy makers require improved monitoring and Environmental Risk Assessment to protect microbial diversity and functions in contaminated ecosystems.
Pharm-ERA proposes a high-level interdisciplinary and intersectoral research and training network based on 10 doctoral projects covering scientific disciplines including environmental and analytical chemistry, microbial ecology, ecotoxicology, molecular biology (incl. multi-omics approaches) and chemical fate/effect modelling. Pharm-ERA involves 9 Beneficiaries (including 2 non-academics) and 6 Associated Partners (including 5 non-academics), committed to contribute to research, training, dissemination, communication and exploitation of results targeting end-users such as Environmental consultancies and agencies.
Pharm-ERA will provide EU with high-level scientific experts who will further shape and implement the next generation of environmental management strategies, EU guidelines and regulations to reduce the adverse environmental effects and risks of pharmaceuticals and the spread of antimicrobial resistance and pathogens in terrestrial and aquatic environments. This will ensure sustainability of our ecosystems, fostering positive impacts on human and animal health and well-being far beyond the Pharm-ERA project
Fields of science
- natural scienceschemical sciencesanalytical chemistry
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencesearth and related environmental sciencesenvironmental sciencespollution
- natural sciencesbiological sciencesecologyecosystems
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Keywords
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinator
75007 Paris
France
See on map
Participants (7)
29027 Podenzano
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
28006 Madrid
See on map
38080 L Isle D Abeau
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
04318 Leipzig
See on map
405 30 Goeteborg
See on map
38221 Volos
See on map
08500 Vic Barcelona
See on map
Partners (12)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
MST 1761 Mosta
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
8600 Dubendorf
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
75794 Paris
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
08211 Castellar Del Valles
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
118 54 Athens
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
26300 Alixan
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
80539 MUNCHEN
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
08007 Barcelona
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
33000 Bordeaux
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
69622 Villeurbanne Cedex
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
20123 Milano
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
17004 Girona
See on map